Research programme: antibody therapeutics - Genmab/Medarex

Drug Profile

Research programme: antibody therapeutics - Genmab/Medarex

Latest Information Update: 10 Oct 2008

Price : $50

At a glance

  • Originator Genmab; SEQUENOM
  • Developer Medarex
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Diabetes mellitus; Obesity; Osteoporosis

Most Recent Events

  • 10 Oct 2008 Discontinued - Preclinical for Cardiovascular disorders in Europe (unspecified route)
  • 10 Oct 2008 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
  • 10 Oct 2008 Discontinued - Preclinical for Diabetes mellitus in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top